A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

Abstract

Acute myeloid leukemia with mutated NPM1 gene and aberrant cytoplasmic expression of nucleophosmin (NPMc + acute myeloid leukemia) shows distinctive biological and clinical features. Experimental evidence of the oncogenic potential of the nucleophosmin mutant is, however, still lacking, and it is unclear whether other genetic lesion(s), e.g. FLT3 internal tandem duplication, cooperate with NPM1 mutations in acute myeloid leukemia development. An analysis of age-specific incidence, together with mathematical modeling of acute myeloid leukemia epidemiology, can help to uncover the number of genetic events needed to cause leukemia. We collected data on age at diagnosis of acute myeloid leukemia patients from five European Centers in Germany, The Netherlands and Italy, and determined the age-specific incidence of AML with mutated NPM1 (a total of 1,444 cases) for each country. Linear regression of the curves representing age-specific rates of diagnosis per year showed similar slopes of about 4 on a double logarithmic scale. We then adapted a previously designed mathematical model of hematopoietic tumorigenesis to analyze the age incidence of acute myeloid leukemia with mutated NPM1 and found that a one-mutation model can explain the incidence curve of this leukemia entity. This model fits with the hypothesis that NPMc + acute myeloid leukemia arises from an NPM1 mutation with haploinsufficiency of the wild-type NPM1 allele.Key words: acute myeloid leukemia, nucleophosmin, mutation.

Acute myeloid leukemia in the real world: why population-based registries are needed

“…As a consequence, secondary myelodysplasia and AML are increasing by age (Figure 2). However, the age distribution could also be explained by single-hit mutations, [26][27][28] and the proportion of AML arising in patients with prior myelodysplasia or myeloproliferative neoplasia is not as different by age as the overall survival (OS; Figure 3). Therapy-related AML constitutes only approximately 5% of AML, with a female predominance because of chemotherapy for female cancers.…”

Late relapse of acute myeloid leukemia with mutated NPM1 after eight years: evidence of NPM1 mutation stability

“…8 Recent data indicate that this agent may have a protective role of renal parenchyma due to inhibition of NFκB activity.…”

Cell Division Patterns in Acute Myeloid Leukemia Stem-like Cells Determine Clinical Course: A Model to Predict Patient Survival

“…[28][29][30][31][32][33]. They offer the possibility to comprehend processes not yet accessible by experimental measurements (5).…”